News

The investment funds will be used by Applied Genetic Technologies Corporation (AGTC) to complete the next phase in human clinical trials for its gene therapy treatments for alpha-1

Patrick Soon-Shiong, who held the positions of chairman and CEO of Abraxis BioScience since founding the company, will assume the role of executive chairman and CEO of Abraxis

The FIRCA program is intended to benefit the research interests of both collaborators while increasing research capacity at the foreign site. Each institution will receive between $33,000 and

With CE Mark approval, IMRIS will immediately commence marketing in Europe of two products: IMRISNV for stroke management and advanced neurovascular interventions and IMRIScardio for cardiovascular interventions. According

In this role, Dr Superko will provide medical leadership for Celera’s cardiovascular products and services through oversight of education programs and participation in relevant medical associations, professional societies

Thermage is a non-invasive radiofrequency procedure for tightening and contouring skin. Stephen Fanning, chairman of the board, president and CEO of Solta Medical, said: “We are excited about

The initial products will be directed to the ovarian cancer biomarker, HE4, which is FDA-cleared for monitoring the progression or recurrence of epithelial ovarian cancer. Fujirebio also grants

US-based ZymoGenetics has reduced its workforce by approximately 32%, or 161 employees, as part of a corporate restructuring. ZymoGenetics said that it is reorganizing its operations to focus

US-based Medicis and French pharmaceutical company Ipsen have reported that the FDA has approved the biologics license application for Dysport, an acetylcholine release inhibitor and a neuromuscular blocking